14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $141.16 $183.01 Friday, 3rd May 2024 MDGL stock ended at $229.84. This is 6.38% more than the trading day before Thursday, 2nd May 2024. During the day the stock fluctuated 5.88% from a day low at $221.25 to a day high of $234.25.
90 days $141.16 $227.30
52 weeks $84.73 $227.30

Historical Madrigal Pharmaceuticals, Inc. prices

Date Open High Low Close Volume
Mar 28, 2024 $258.54 $268.22 $254.87 $267.04 435 650
Mar 27, 2024 $250.00 $259.53 $244.85 $258.81 398 840
Mar 26, 2024 $247.00 $251.99 $246.61 $247.62 229 626
Mar 25, 2024 $248.85 $257.48 $246.54 $247.62 346 116
Mar 22, 2024 $258.49 $258.52 $242.38 $248.20 523 911
Mar 21, 2024 $261.64 $265.27 $251.79 $255.27 368 265
Mar 20, 2024 $267.50 $267.50 $251.51 $258.99 674 354
Mar 19, 2024 $275.00 $276.67 $263.51 $265.68 907 420
Mar 18, 2024 $274.48 $292.86 $272.01 $283.23 938 031
Mar 15, 2024 $293.90 $299.98 $262.00 $270.37 2 752 926
Mar 14, 2024 $274.58 $276.30 $236.64 $243.57 841 088
Mar 13, 2024 $267.00 $275.02 $265.01 $272.98 764 949
Mar 12, 2024 $268.00 $269.68 $258.08 $262.67 571 456
Mar 11, 2024 $258.21 $266.83 $253.00 $260.15 678 381
Mar 08, 2024 $256.96 $261.99 $252.72 $255.32 465 595
Mar 07, 2024 $258.00 $259.94 $248.53 $251.03 400 374
Mar 06, 2024 $259.99 $270.98 $256.32 $257.38 676 439
Mar 05, 2024 $244.44 $249.39 $238.93 $248.49 377 594
Mar 04, 2024 $255.00 $260.00 $243.17 $246.56 500 027
Mar 01, 2024 $237.38 $252.50 $237.33 $251.63 425 049
Feb 29, 2024 $259.11 $261.99 $235.50 $236.20 495 010
Feb 28, 2024 $239.10 $254.29 $237.69 $254.23 483 960
Feb 27, 2024 $233.85 $242.97 $233.06 $239.80 356 129
Feb 26, 2024 $221.00 $241.63 $214.00 $232.57 776 706
Feb 23, 2024 $249.36 $249.98 $235.10 $236.54 466 166
Click to get the best stock tips daily for free!

About Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals. Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745,... MDGL Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT